Life is a gift, I prefer it in CASH.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VNDB - 0.0034 x 0.0035 down 2% on huge volume - still hopeful for a run here, lots of buzz
VNDB - 0.0034 x 0.0035 - need to keep the pressure on the ask.
VNDB - starting to see some buying pressure
I agree Bruce, it all has to be on the ask side.
VNDB is in a great spot for a true reverse and run - IMO
52Wk Low 0.0017 - 52Wk High 0.1070
Morning Trade for profits. VNDB nice start great volume lets keep the pressure on and break this wide open today.
VNDB - news out - VNDB news:Vendum Batteries Inc. Retains Morningstar Corporate Communications
EL SEGUNDO, CA, Sep 10, 2012 (MARKETWIRE via COMTEX) -- Vendum Batteries (OTCQB: VNDB), a battery technology development company, is pleased to announce that it has retained Morningstar Corporate Communications to provide the company with investor and public relations related services. Vendum Batteries expects that Morningstar will assist in generating the required investor and public attention to further develop their breakthrough paper battery technology.
Rune Vind, Vendum's CEO and President, is excited to be working with Morningstar. "We look forward to strengthening our shareholder communications and increasing our visibility to potential investors through this new relationship," he said. "Morningstar will help ensure that meaningful company information will be released in a timely fashion and will be easily accessible to a broad audience."
Chris Dove, president of Morningstar, stated, "We are pleased to be working with Mr. Vind and his team." He sees Vendum's paper battery technology as potentially revolutionary and states that "Morningstar appreciates the opportunity to be a part of the company's development and success."
About Vendum Batteries Inc.
Vendum Batteries has a pending patent on a non-toxic, carbon-based light-weight battery. The paper-thin battery will contain none of the toxic elements used in conventional batteries and its cutting edge carbon nanotube and cellulose-based technology makes it entirely biodegradable. The Vendum Battery will be developed from its current low power capacity, to soon accommodate the ever-increasing global demand for durable battery power for cell phones, iPods, human implants and eventually electrical vehicles etc.
Americans purchase around 5 billion batteries, leaving 146,000 tons of battery waste behind, and given that the worldwide personal battery use is a growing $63 billion industry, the potential of this revolutionary non-toxic technology could be enormous. With growing support for the idea of replacing toxic, polluting energy sources with clean, non-toxic and biodegradable resources, there has never been a better time for Vendum's breakthrough technology.
About Morningstar Corporate Communications
Morningstar is a full service investor relations and corporate communications firm specializing in small-cap companies. Morningstar is located in Panama with partners and contacts worldwide. By combining traditional IR with the latest online marketing Morningstar attracts investors and creates value for the shareholders of client companies.
Disclaimer - Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements; projected events in this press release may not occur due to unforeseen circumstances, various factors, and other risks identified in a company's annual report on Form 10-K and other filings made by such company.
Contacts:
Vendum Batteries Inc.
Investor relations
USA toll free 1(888) 426-1116
or NY local 1(646) 224-5914
vendum@mscorpcommunications.com
www.vendumbatteries.com
SOURCE: Vendum Batteries Inc.
CONTACT: mailto:vendum@mscorpcommunications.com
http://www.vendumbatteries.com/
VNDB - news out - VNDB news:Vendum Batteries Inc. Retains Morningstar Corporate Communications
EL SEGUNDO, CA, Sep 10, 2012 (MARKETWIRE via COMTEX) -- Vendum Batteries (OTCQB: VNDB), a battery technology development company, is pleased to announce that it has retained Morningstar Corporate Communications to provide the company with investor and public relations related services. Vendum Batteries expects that Morningstar will assist in generating the required investor and public attention to further develop their breakthrough paper battery technology.
Rune Vind, Vendum's CEO and President, is excited to be working with Morningstar. "We look forward to strengthening our shareholder communications and increasing our visibility to potential investors through this new relationship," he said. "Morningstar will help ensure that meaningful company information will be released in a timely fashion and will be easily accessible to a broad audience."
Chris Dove, president of Morningstar, stated, "We are pleased to be working with Mr. Vind and his team." He sees Vendum's paper battery technology as potentially revolutionary and states that "Morningstar appreciates the opportunity to be a part of the company's development and success."
About Vendum Batteries Inc.
Vendum Batteries has a pending patent on a non-toxic, carbon-based light-weight battery. The paper-thin battery will contain none of the toxic elements used in conventional batteries and its cutting edge carbon nanotube and cellulose-based technology makes it entirely biodegradable. The Vendum Battery will be developed from its current low power capacity, to soon accommodate the ever-increasing global demand for durable battery power for cell phones, iPods, human implants and eventually electrical vehicles etc.
Americans purchase around 5 billion batteries, leaving 146,000 tons of battery waste behind, and given that the worldwide personal battery use is a growing $63 billion industry, the potential of this revolutionary non-toxic technology could be enormous. With growing support for the idea of replacing toxic, polluting energy sources with clean, non-toxic and biodegradable resources, there has never been a better time for Vendum's breakthrough technology.
About Morningstar Corporate Communications
Morningstar is a full service investor relations and corporate communications firm specializing in small-cap companies. Morningstar is located in Panama with partners and contacts worldwide. By combining traditional IR with the latest online marketing Morningstar attracts investors and creates value for the shareholders of client companies.
Disclaimer - Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements; projected events in this press release may not occur due to unforeseen circumstances, various factors, and other risks identified in a company's annual report on Form 10-K and other filings made by such company.
Contacts:
Vendum Batteries Inc.
Investor relations
USA toll free 1(888) 426-1116
or NY local 1(646) 224-5914
vendum@mscorpcommunications.com
www.vendumbatteries.com
SOURCE: Vendum Batteries Inc.
CONTACT: mailto:vendum@mscorpcommunications.com
http://www.vendumbatteries.com/
VNDB - lots of buzz this morning ...
"The revolutionizing new battery technology that Vendum is developing will bring significant benefits to users, shareholders and the environment"
Security Details
Market Value- $1,886,164 a/o Sep 07, 2012
Shares Outstanding- 523,934,496 a/o Aug 13, 2012
Float -Not Available
Authorized Shares -750,000,000 a/o Feb 02, 2011
http://www.vendumbatteries.com
"The flexible shape will allow the Vendum paper battery to be used in small or irregularly-shaped electronics"
VNDB - lots of buzz this morning ...
"The revolutionizing new battery technology that Vendum is developing will bring significant benefits to users, shareholders and the environment"
Security Details
Market Value- $1,886,164 a/o Sep 07, 2012
Shares Outstanding- 523,934,496 a/o Aug 13, 2012
Float -Not Available
Authorized Shares -750,000,000 a/o Feb 02, 2011
http://www.vendumbatteries.com
"The flexible shape will allow the Vendum paper battery to be used in small or irregularly-shaped electronics"
VNDB - check out the chart -
OVERVIEW:
Ground-breaking nano-technology – a paper-thin sheet of cellulose infused with aligned carbon nanotubes that act as electricity conducting electrodes.
Ecological - no mercury, lead, chromium, cadmium or other heavy metals that are found in today’s batteries, and no ozone-depleting solvents used in production; 90% composed of cellulose, the same plant cell used in paper products.
Temperature resistant - the lack of water content means it can function in temperatures up to 300 degrees Fahrenheit and down to 100 below zero.
Biocompatible - the paper battery will eventually be capable of powering a small device such as a pacemaker or cochlear implant without introducing any harsh chemicals - such as the kind that are typically found in batteries - into the body. Early indications show that with further development, the paper battery could be energized by the electrolyte emitted from one's own blood or body sweat!
Flexible - the device can be rolled, twisted, folded, or cut into any number of shapes with no loss of mechanical integrity or efficiency. As development progresses, the paper batteries will be stackable, like a ream of printer paper, to boost the total power output. When power output grows, the paper battery will be able to be moulded into different shapes, such as a car door, a flashlight, or PDA, which would enable important new engineering innovations.
A better alternative - the paper battery will provide a low, steady power output, as well as have a super-capacitor’s quick burst of energy - and while a conventional battery contains a number of separate components, the Vendum paper battery will integrate all of the battery components in a single structure, making it more energy efficient and lighter.
VNDB - check out the chart -
OVERVIEW:
Ground-breaking nano-technology – a paper-thin sheet of cellulose infused with aligned carbon nanotubes that act as electricity conducting electrodes.
Ecological - no mercury, lead, chromium, cadmium or other heavy metals that are found in today’s batteries, and no ozone-depleting solvents used in production; 90% composed of cellulose, the same plant cell used in paper products.
Temperature resistant - the lack of water content means it can function in temperatures up to 300 degrees Fahrenheit and down to 100 below zero.
Biocompatible - the paper battery will eventually be capable of powering a small device such as a pacemaker or cochlear implant without introducing any harsh chemicals - such as the kind that are typically found in batteries - into the body. Early indications show that with further development, the paper battery could be energized by the electrolyte emitted from one's own blood or body sweat!
Flexible - the device can be rolled, twisted, folded, or cut into any number of shapes with no loss of mechanical integrity or efficiency. As development progresses, the paper batteries will be stackable, like a ream of printer paper, to boost the total power output. When power output grows, the paper battery will be able to be moulded into different shapes, such as a car door, a flashlight, or PDA, which would enable important new engineering innovations.
A better alternative - the paper battery will provide a low, steady power output, as well as have a super-capacitor’s quick burst of energy - and while a conventional battery contains a number of separate components, the Vendum paper battery will integrate all of the battery components in a single structure, making it more energy efficient and lighter.
VNDB - thinking she is ready to reverse !!
Website: http://www.vendumbatteries.com
Security Details
Market Value- $1,886,164 a/o Sep 07, 2012
Shares Outstanding- 523,934,496 a/o Aug 13, 2012
Float -Not Available
Authorized Shares -750,000,000 a/o Feb 02, 2011
Ford - broke $10.00 this morning - looking very bullish - looking to get back in on the next dip, next leg up will be to test $11.00.
Solid play going forward....
WASHINGTON (Reuters) - Jobs growth slowed sharply in August, setting the stage for the Federal Reserve to pump additional money into the sluggish economy next week and dealing a blow to President Obama as he seeks reelection in November.
Nonfarm payrolls increased only 96,000 last month, the Labor Department said on Friday. While the unemployment rate dropped to 8.1 percent from 8.3 percent in July, that was because so many Americans gave up the hunt for work.
The survey of households from which the jobless rate is derived showed a drop in employment. The lackluster report keeps the pressure on Obama ahead of the November vote in which the health of the economy looms large.
"This weak employment report, in jobs, wages, hours worked and participation is probably the last piece the Fed needs before launching another round of quantitative easing next week," said Joseph Trevisani, chief market strategist at Worldwide Markets in Woodcliff Lake, New Jersey.
U.S. stock index futures pared their gains on the report, while Treasury debt prices turned positive. The dollar extended its losses versus the euro.
Economists polled by Reuters had expected payrolls to rise 125,000 last month, but some had pushed their forecasts higher after upbeat data on Thursday.
Fed Chairman Ben Bernanke last week said the labor market's stagnation was a "grave concern," a comment that raised expectations for a further easing of monetary policy as soon as the central bank's meeting on Wednesday and Thursday.
The economy has experienced three years of growth since the 2007-09 recession, but the expansion has been grudging and the jobless rate has held above 8 percent for more than three years -- the longest stretch since the Great Depression.
The jobless rate peaked at 10 percent in October 2009, but progress reducing it stalled this year, threatening Obama's bid for a second term. An online Reuters/Ipsos poll on Thursday gave Republican Challenger Mitt Romney a 1-point edge on Obama, 45 percent to 44 percent.
The lack of headway putting Americans back to work has also put the question of further monetary stimulus on the table at the Fed. The central bank has held interest rates close to zero for nearly four years and pumped about $2.3 trillion into the economy through two bouts of bond buying.
AMERICANS GIVE UP SEARCHING FOR WORK
The weak tenor of the employment report was also emphasized by revisions to June and July data to show 41,000 fewer jobs created than previously reported.
In addition, the labor force participation rate, or the percentage of Americans who either have a job or are looking for one, fell to 63.5 percent -- the lowest since September 1981.
A total of 368,000 people gave up looking for work in August, the household survey showed.
Since the beginning of the year, job growth has averaged 139,000 per month, compared with an average monthly gain of 153,000 in 2011.
Economists blame fears of the so-called U.S. fiscal cliff -- the $500 billion or so in expiring tax cuts and government spending reductions set to take hold at the start of next year unless Congress acts -- and Europe's long-running debt problems, for the slowdown in hiring.
Job creation last month was weak across the board, with manufacturing payrolls falling 15,000, the first decline since September last year. Factory jobs were inflated in July because automobile manufacturers kept plants running when they would normally shut them for retooling.
There was little improvement in construction employment, which added 1,000 jobs. Temporary hiring fell 4,900, declining for the first time since March.
Utilities payrolls saw a snap back, adding 8,800 after being depressed by the strike of about 9,000 workers in July.
Government payrolls declined 7,000, falling for a sixth straight month.
Average hourly earnings fell one cent last month, highlighting the underlying weakness in the labor market. Earnings have risen 1.7 percent over the past 12 months.
The average work week was steady at 34.4 hours in August.
ENTB head faked us. Would love to see it hold the 50MA at 0.0054 as support.
ENTB head faked us. Would love to see it hold the 50MA at 0.0054 as support.
ENTB losing its gains from earlier in the day - head faked us. Would ove to see it hold the 50MA at 0.0054 as support
ENTB looking for a strong close today -
ENTB -down - 34.5 mil in volume traded needs to close above 0.0057 - time to pushhhhhhhhhhh - Lets close green get set for next leg up
ENTB 0.0052 x 0.006 - up 20%
She is going to break and run - like the way she is trading today !
Witnessing some good buying pressure - ENTB volume over 15 million so far in todays trading up 22%
ENTB come on baby run - she is so close....
ENTB thinning out - she is getting ready to pop !!
ENTB - nice post ziggy - stock is getting jiggy this morning !
ENTB up 30% about to drop 65's from the ask !
I am a beliver - ENTB has got momo, done churning now about to start running !
ENTB has found its legs - 0.0062 x 0.0063 - broke upper bolly band.
ENTB liking what I see.
ENTB thin to 0.007 !
ENTB looking good in the early going - up 30% - she is ready to run !!
ENTB is ready !!
ENTB out of the box strong this morning
ENTB news out - Entest BioMedical Inc. (OTCQB: ENTB) a company focused on veterinary biotechnology and veterinary hospital acquisition / operation, announced today that the company's recent research study conducted on ImenVax™ (Entest's Immuno-therapeutic cancer vaccine for dogs), ImenVax™ appears to show signs of slowing tumor growth in advanced cases of oral melanoma, while being well tolerated by patients.
"Principal investigators conducting the safety study on ImenVax™ observed the implantation device and vaccine to be very well-tolerated," stated Entest BioMedical Chairman & CEO David Koos. "There was only one case where the patient had a minor skin irritation. In all of the cases studied the size of the tumors were likely too extensive to allow for objective response with ImenVax™ as single agent therapy. The company's researchers stated that subjectively, tumor progression was slowed during the period that the implant was present and accelerated after removal in 2 patients. The report recommends that further evaluation in patients with lesser tumor burden is warranted, along with cytokine stimulation."
Dr. Koos continued, "Our ImenVax™ immune-therapeutic cancer vaccine is designed to treat dogs with oral melanoma while limiting the side effects of treatment. We anticipate that within the next 16 months, we will have the capacity to treat just over 3,000 patients yearly throughout our veterinary clinics."
A Spokesperson for the Company noted the National Canine Cancer Foundation says one in three dogs will be impacted by cancer. This staggering statistic shows not only the need for a cost effective treatment but also a treatment that is well tolerated. The potential revenue generated per patient is approximately $3,000 according to industry statistics. Management indicates that each veterinary hospital Entest will seek to acquire over the next two years will have a preexisting patient flow of at least 700 cancer patients per year. Once the first 10 veterinary hospitals have been acquired, Entest could possibly see 7,000 treatable canine patients per year at $3,000 per patient. This meaning, should Entest be successful in meeting its veterinary hospital acquisition target numbers [10 facilities], the company could potentially command revenues reflecting as much as $21 million per annum; treating dogs with cancer.
Dr. Koos concluded, "Our ImenVax™ immuno-therapeutic cancer vaccine is being designed to utilize the patient's own immune system to battle the cancer; potentially making it a less invasive and less traumatic alternative for pet owners than chemotherapy and radiation therapy. Also, the safety study is being conducted on dogs suffering from oral melanoma. We have no intention to simply stop at oral melanoma applications. Entest is working with an incredibly experienced research team in hopes to increase efficacy in extreme cases by the inclusion of cytokine stimulation. We anticipate at some point in the near future, to begin clinical trials as we will ultimately seek USDA or FDA approval to further the reach of our ImenVax™ canine cancer treatment."
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCQB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Entest BioMedical Inc.
David R. Koos
Chairman & CEO
ENTB - Entest BioMedical Inc. (OTCQB: ENTB) a company focused on veterinary biotechnology and veterinary hospital acquisition / operation, announced today that the company's recent research study conducted on ImenVax™ (Entest's Immuno-therapeutic cancer vaccine for dogs), ImenVax™ appears to show signs of slowing tumor growth in advanced cases of oral melanoma, while being well tolerated by patients.
"Principal investigators conducting the safety study on ImenVax™ observed the implantation device and vaccine to be very well-tolerated," stated Entest BioMedical Chairman & CEO David Koos. "There was only one case where the patient had a minor skin irritation. In all of the cases studied the size of the tumors were likely too extensive to allow for objective response with ImenVax™ as single agent therapy. The company's researchers stated that subjectively, tumor progression was slowed during the period that the implant was present and accelerated after removal in 2 patients. The report recommends that further evaluation in patients with lesser tumor burden is warranted, along with cytokine stimulation."
Dr. Koos continued, "Our ImenVax™ immune-therapeutic cancer vaccine is designed to treat dogs with oral melanoma while limiting the side effects of treatment. We anticipate that within the next 16 months, we will have the capacity to treat just over 3,000 patients yearly throughout our veterinary clinics."
A Spokesperson for the Company noted the National Canine Cancer Foundation says one in three dogs will be impacted by cancer. This staggering statistic shows not only the need for a cost effective treatment but also a treatment that is well tolerated. The potential revenue generated per patient is approximately $3,000 according to industry statistics. Management indicates that each veterinary hospital Entest will seek to acquire over the next two years will have a preexisting patient flow of at least 700 cancer patients per year. Once the first 10 veterinary hospitals have been acquired, Entest could possibly see 7,000 treatable canine patients per year at $3,000 per patient. This meaning, should Entest be successful in meeting its veterinary hospital acquisition target numbers [10 facilities], the company could potentially command revenues reflecting as much as $21 million per annum; treating dogs with cancer.
Dr. Koos concluded, "Our ImenVax™ immuno-therapeutic cancer vaccine is being designed to utilize the patient's own immune system to battle the cancer; potentially making it a less invasive and less traumatic alternative for pet owners than chemotherapy and radiation therapy. Also, the safety study is being conducted on dogs suffering from oral melanoma. We have no intention to simply stop at oral melanoma applications. Entest is working with an incredibly experienced research team in hopes to increase efficacy in extreme cases by the inclusion of cytokine stimulation. We anticipate at some point in the near future, to begin clinical trials as we will ultimately seek USDA or FDA approval to further the reach of our ImenVax™ canine cancer treatment."
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCQB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Entest BioMedical Inc.
David R. Koos
Chairman & CEO
ENTB news out - looking for this to break upper bolly and 50 MA today !
Entest BioMedical Inc. (OTCQB: ENTB) a company focused on veterinary biotechnology and veterinary hospital acquisition / operation, announced today that the company's recent research study conducted on ImenVax™ (Entest's Immuno-therapeutic cancer vaccine for dogs), ImenVax™ appears to show signs of slowing tumor growth in advanced cases of oral melanoma, while being well tolerated by patients.
"Principal investigators conducting the safety study on ImenVax™ observed the implantation device and vaccine to be very well-tolerated," stated Entest BioMedical Chairman & CEO David Koos. "There was only one case where the patient had a minor skin irritation. In all of the cases studied the size of the tumors were likely too extensive to allow for objective response with ImenVax™ as single agent therapy. The company's researchers stated that subjectively, tumor progression was slowed during the period that the implant was present and accelerated after removal in 2 patients. The report recommends that further evaluation in patients with lesser tumor burden is warranted, along with cytokine stimulation."
Dr. Koos continued, "Our ImenVax™ immune-therapeutic cancer vaccine is designed to treat dogs with oral melanoma while limiting the side effects of treatment. We anticipate that within the next 16 months, we will have the capacity to treat just over 3,000 patients yearly throughout our veterinary clinics."
A Spokesperson for the Company noted the National Canine Cancer Foundation says one in three dogs will be impacted by cancer. This staggering statistic shows not only the need for a cost effective treatment but also a treatment that is well tolerated. The potential revenue generated per patient is approximately $3,000 according to industry statistics. Management indicates that each veterinary hospital Entest will seek to acquire over the next two years will have a preexisting patient flow of at least 700 cancer patients per year. Once the first 10 veterinary hospitals have been acquired, Entest could possibly see 7,000 treatable canine patients per year at $3,000 per patient. This meaning, should Entest be successful in meeting its veterinary hospital acquisition target numbers [10 facilities], the company could potentially command revenues reflecting as much as $21 million per annum; treating dogs with cancer.
Dr. Koos concluded, "Our ImenVax™ immuno-therapeutic cancer vaccine is being designed to utilize the patient's own immune system to battle the cancer; potentially making it a less invasive and less traumatic alternative for pet owners than chemotherapy and radiation therapy. Also, the safety study is being conducted on dogs suffering from oral melanoma. We have no intention to simply stop at oral melanoma applications. Entest is working with an incredibly experienced research team in hopes to increase efficacy in extreme cases by the inclusion of cytokine stimulation. We anticipate at some point in the near future, to begin clinical trials as we will ultimately seek USDA or FDA approval to further the reach of our ImenVax™ canine cancer treatment."
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCQB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Entest BioMedical Inc.
David R. Koos
Chairman & CEO